Some individuals on probation who have opioid use disorders (OUDs) cannot access effective, FDA-approved medications-methadone, buprenorphine, and naltrexone-to treat their disorders. This article shared finding from a survey of 26 Illinois probation department directors on how probation departments respond to clients with OUDs, focusing on the barriers to accessing OUD medications. The article noted that a majority of probation department leaders perceived barriers for probation client access to OUD medications including lack of medical personnel experience, cost, need for guidance on medications, and regulations prohibiting medication use. The article highlighted a need for training, interagency collaboration, and policy changes to increase access to, education on, and use of, medications for probation clients. Such efforts may result in positive outcomes such as reduced recidivism, increased quality of life, and reduced mortality.
Review the Article HERE